US private equity firm KKR is to acquire a majority stake in JB Chemicals, accelerating the Indian group's growth plans in branded formulations. Post a 54% stake acquisition for $414m via part-purchase from the founders and an open offer at INR745 per share, KKR's final stake could rise to 64.9% if founders offer more shares.
Private equity firms are having a busy year in India. In its second investment in as many months, US PE group KKR has agreed to acquire a majority stake in JB Chemicals & Pharmaceuticals Ltd..
Post a 54% stake acquisition for INR31bn ($414m) via part-purchase from the founding JB Mody family and an open offer...
Stay ahead of every shift in generics and biosimilars.
Generics Bulletin brings you the latest updates that matter for the off-patent industry.
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.